Loading clinical trials...
Loading clinical trials...
Pilot Phase 1 Clinical Trial of PET Scanning in Tau Protein Deposition and Connectome Analysis in Traumatic Encephalopathy Syndrome (TES) Cohort With a Probable Chronic Traumatic Encephalopathy (CTE) Pattern of Neurodegenerative Disease
Conditions
Interventions
[18F] PI-2620 Tau Ligand
Locations
1
Australia
Macquarie Medical Imaging
Macquarie Park, New South Wales, Australia
Start Date
February 3, 2023
Primary Completion Date
May 30, 2023
Completion Date
December 31, 2024
Last Updated
February 28, 2024
NCT07339319
NCT03724136
NCT04303065
NCT04928534
NCT04489082
NCT04993495
Lead Sponsor
Macquarie University, Australia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions